BibTex RIS Cite

Effect of Coasting on Success of In-Vitro Fertilization Cycles

Year 2016, Volume: 2 Issue: 2, 101 - 106, 01.04.2016

Dilek Benk Silfeler İsmet Gun Raziye Keskin Kurt Ali Ovayolu Kenan Sofuoglu Tayfun Kutlu Naciye Arat

https://doi.org/10.5455/umj.20160703095058

Abstract

Introduction: “Coasting” is a method used in prevention of Ovarian Hyperstimulation Syndrome OHSS during In Vitro Fertilization IVF cycles. Coasting refers to witholding exogenous gonodotropine usage and delaying the administration of hCG in high risk cycles until serum estradiol levels falls into an acceptable range. The aim of our study is to evaluate coasting effect on IVF oucomes in patients with E2 levels of 4000-5000 pikogram. Method: This study was a single centered, retrospective and a case-control study. Study population were selected from women applied Zeynep Kamil Research Hospital IVF department between January 2003 and December 2013 n:7850 . Patients were divided in 2 groups as conrol group Group 1, n:48 and coasted group Group 2, n:34 according to whether or not coasting performed. Results: E2 levels on the day of hCG in group 2 were significiantly lower than group 1 4332.6±256.6 and 3180.8±702.9; p

Keywords

Coasting in-vitro fertilization E2 levels

References

  • 1.Aljawoan FY, Hunt LP, Gordon UD. Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. J Hum Reprod Sci 2012; 5(1): 32–36.
  • 2. Vitthala S, Bouaziz J, Tozer A, Zosmer A, Al-Shawaf T. Serum FSH Levels in Coasting Programmes on the hCG Day and Their Clinical Outcomes in IVF±ICSI Cycles. Int J Endocrinol 2012: 540681
  • 3. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstetrics & Gynaecology 2002; 12: 111–116.
  • 4. Abulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: Classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9(3): 275–289
  • 5. Al-Shawaf T, Zosmer A, Hussain A et al. Prevention ofsevere ovarian hyperstimulation syndrome in IVF with orwithout ICSI and embryo transfer: a modified coasting”strategy based on ultrasound for identification of high-riskpatients. Hum Reprod 2001; 16(1): 24–30
  • 6. Sher G, Zouves C, Feinman M, and Maassarani G. Prolonged coasting: an elective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 1995; 10(12): 3107–3109
  • 7. Benadiva CA, Moomjy M, Davis O, Liu HC, Kligman I, and Rosenwaks Z. Withholding gonadotropin administration is an elective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997; 67(4): 724–727
  • 8. Tortoriello DV, McGovern PG, Colon JM, Skurnick JH, Lipetz K, Santoro N. “Coasting” does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998; 69(3): 454–460
  • 10. D’Angelo A, Amso N. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011 15; (6)
  • 11. Grochowski D, Wołczyński S, Kuczyński W et al. Timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program. Gynecol Endocrinol 2001; 15(3): 234–238
  • 12. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002; 17(2): 310–313
  • 13. Nardo LG, Cheema P, Gelbaya TA et al. The optimal length of “coasting protocol” in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization. Hum Fertil (Camb) 2006; 9(3): 175–180
  • 14. Cao XW, Lin K, Li CY, Yuan CW. A review of WHO Laboratory Manual for the Examination and Processing of Human Semen (5th edition). Zhonghua Nan Ke Xue 2011; 17(12): 1059–1063
  • 15. Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988; 541: 259-74.
  • 16. Gardner DK, Lane M, Stevens J. Non-invasive assessment of human embryo nutrient consumption as a measure of developmental potential. Fertil Steril 2001; 76(6): 1175–1180
  • 17. D’Angelo A, Amso N. Coasting (withholding gonadotropins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002; (3): CD002811
  • 18. García-Velasco JA, Zúñiga A, Pacheco A et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod 2004; 19(7): 1530–1538
  • 19. Lyons CA, Wheeler CA, Frishman GN. Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9(5): 792–799
  • 20. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58(2): 249–261
  • 21. Asch RH, Li HP, Balmaceda JP, Weckstein LN. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: Definition of high risk groups. Hum Reprod 1991; 6(10):1395-1939
  • 22. Delvigne A, Dubois M, Batthe B et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993; 8(9): 1361–1366
  • 23. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number insevere ovarian hyperstimulation syndrome. Hum Reprod 1995; 10(4): 811–814
  • 24. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Obstet Gynaecol Reprod Med 2008; 18: 18–22
  • 26. Abdallah R, Kligman I, Davis O, Rosenwaks Z. Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med. 2010; 28(6): 486–492
  • 27. Levinsohn-Tavor O, Friedler S, Schachter M, Raziel A, Strassburger D, Ron-El R. Coasting-what is the best formula? Hum Reprod 2003; 18(5): 937–940
  • 28. Moon HS, Joo BS, Moon SE, Lee SK, Kim KS, Koo JS. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. Fertil Steril 2008; 90(6): 2172–2178
  • 29. Ulug U, Ben-Shlomo I, Bahceci M. Predictors of success during coasting period in high-responder patients undergoing controlled ovarian stimulation for assisted conception. Fertil Steril 2004; 82(2): 338–342
  • 30. Juan A, Veronica I, Guillermo Q, Antonio P. Coasting for the prevention of ovarian hyperstimulation syndrome: Much ado about nothing. Fertil Steril 2006; 85(3): 547–554
  • 31. Farhi J, Ben-Haroush A, Lande Y, Sapir O, Pinkas H, Fisch B. In vitro fertilization cycle outcome after coasting in gonadotropinreleasing hormone (GnRH) agonist versus GnRH antagonist protocols. Fertil Steril 2009; 91(2):377–382

Year 2016, Volume: 2 Issue: 2, 101 - 106, 01.04.2016

Dilek Benk Silfeler İsmet Gun Raziye Keskin Kurt Ali Ovayolu Kenan Sofuoglu Tayfun Kutlu Naciye Arat

https://doi.org/10.5455/umj.20160703095058

Abstract

References

  • 1.Aljawoan FY, Hunt LP, Gordon UD. Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. J Hum Reprod Sci 2012; 5(1): 32–36.
  • 2. Vitthala S, Bouaziz J, Tozer A, Zosmer A, Al-Shawaf T. Serum FSH Levels in Coasting Programmes on the hCG Day and Their Clinical Outcomes in IVF±ICSI Cycles. Int J Endocrinol 2012: 540681
  • 3. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstetrics & Gynaecology 2002; 12: 111–116.
  • 4. Abulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: Classifications and critical analysis of preventive measures. Hum Reprod Update 2003; 9(3): 275–289
  • 5. Al-Shawaf T, Zosmer A, Hussain A et al. Prevention ofsevere ovarian hyperstimulation syndrome in IVF with orwithout ICSI and embryo transfer: a modified coasting”strategy based on ultrasound for identification of high-riskpatients. Hum Reprod 2001; 16(1): 24–30
  • 6. Sher G, Zouves C, Feinman M, and Maassarani G. Prolonged coasting: an elective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 1995; 10(12): 3107–3109
  • 7. Benadiva CA, Moomjy M, Davis O, Liu HC, Kligman I, and Rosenwaks Z. Withholding gonadotropin administration is an elective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997; 67(4): 724–727
  • 8. Tortoriello DV, McGovern PG, Colon JM, Skurnick JH, Lipetz K, Santoro N. “Coasting” does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998; 69(3): 454–460
  • 10. D’Angelo A, Amso N. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011 15; (6)
  • 11. Grochowski D, Wołczyński S, Kuczyński W et al. Timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program. Gynecol Endocrinol 2001; 15(3): 234–238
  • 12. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002; 17(2): 310–313
  • 13. Nardo LG, Cheema P, Gelbaya TA et al. The optimal length of “coasting protocol” in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization. Hum Fertil (Camb) 2006; 9(3): 175–180
  • 14. Cao XW, Lin K, Li CY, Yuan CW. A review of WHO Laboratory Manual for the Examination and Processing of Human Semen (5th edition). Zhonghua Nan Ke Xue 2011; 17(12): 1059–1063
  • 15. Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988; 541: 259-74.
  • 16. Gardner DK, Lane M, Stevens J. Non-invasive assessment of human embryo nutrient consumption as a measure of developmental potential. Fertil Steril 2001; 76(6): 1175–1180
  • 17. D’Angelo A, Amso N. Coasting (withholding gonadotropins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002; (3): CD002811
  • 18. García-Velasco JA, Zúñiga A, Pacheco A et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod 2004; 19(7): 1530–1538
  • 19. Lyons CA, Wheeler CA, Frishman GN. Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9(5): 792–799
  • 20. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58(2): 249–261
  • 21. Asch RH, Li HP, Balmaceda JP, Weckstein LN. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: Definition of high risk groups. Hum Reprod 1991; 6(10):1395-1939
  • 22. Delvigne A, Dubois M, Batthe B et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993; 8(9): 1361–1366
  • 23. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number insevere ovarian hyperstimulation syndrome. Hum Reprod 1995; 10(4): 811–814
  • 24. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Obstet Gynaecol Reprod Med 2008; 18: 18–22
  • 26. Abdallah R, Kligman I, Davis O, Rosenwaks Z. Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med. 2010; 28(6): 486–492
  • 27. Levinsohn-Tavor O, Friedler S, Schachter M, Raziel A, Strassburger D, Ron-El R. Coasting-what is the best formula? Hum Reprod 2003; 18(5): 937–940
  • 28. Moon HS, Joo BS, Moon SE, Lee SK, Kim KS, Koo JS. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. Fertil Steril 2008; 90(6): 2172–2178
  • 29. Ulug U, Ben-Shlomo I, Bahceci M. Predictors of success during coasting period in high-responder patients undergoing controlled ovarian stimulation for assisted conception. Fertil Steril 2004; 82(2): 338–342
  • 30. Juan A, Veronica I, Guillermo Q, Antonio P. Coasting for the prevention of ovarian hyperstimulation syndrome: Much ado about nothing. Fertil Steril 2006; 85(3): 547–554
  • 31. Farhi J, Ben-Haroush A, Lande Y, Sapir O, Pinkas H, Fisch B. In vitro fertilization cycle outcome after coasting in gonadotropinreleasing hormone (GnRH) agonist versus GnRH antagonist protocols. Fertil Steril 2009; 91(2):377–382
There are 29 citations in total.

Details

Primary Language English
Journal Section Research Article
Authors

Dilek Benk Silfeler

İsmet Gun This is me

Raziye Keskin Kurt This is me

Ali Ovayolu This is me

Kenan Sofuoglu This is me

Tayfun Kutlu This is me

Naciye Arat This is me

Publication Date April 1, 2016
Published in Issue Year 2016 Volume: 2 Issue: 2

Cite

Vancouver Silfeler DB, Gun İ, Kurt RK, Ovayolu A, Sofuoglu K, Kutlu T, Arat N. Effect of Coasting on Success of In-Vitro Fertilization Cycles. ULUTAS MED J. 2016;2(2):101-6.